Therefore, these data indicated that induction of NRTs by neoantigens could be a potential tactic in treating CRC (Figure1).[12] An investigation showed that the neoantigens from several patients with CRC, including TSHZ3‐L523P, RARA‐R83H, TP53‐R248W, EYA2‐V333I, NRAS‐G12D, TASP1‐P161L, RAP1GAP‐S215R, MOSPD1‐V63I, NAV2‐D1973N, HAVCR2‐F39V, SEC11A‐R11L, SMPDL3B‐T452M, LRFN3‐R118Q, and ULK1‐S248L stimulated a potent NRT response than in peripheral blood lymphocytes obtained from CRC patients. This evidence concerns the gene TP53 and colorectal carcinoma.